(Q33984478)

30 July 2017

1 reference

title

Immunotherapeutic perspective for bispecific antibodies (English)

1 reference

30 July 2017

1 reference

1 reference

van Spriel AB

1

1 reference

30 July 2017

van Ojik HH

series ordinal

2

1 reference

30 July 2017

van De Winkel JG

series ordinal

3

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

21

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

391-397

1 reference

Immunotherapeutic potential of bispecific antibodies

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Mix and match: building manifold binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

An efficient route to human bispecific IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Design and production of novel tetravalent bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

A dimeric bispecific miniantibody combines two specificities with avidity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Resolution of cutaneous inflammation after local elimination of macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Recombinant lipid-tagged antibody fragments as functional cell-surface receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Roles of multiple accessory molecules in T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Bispecific antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Targeting HIV-1 to Fc gamma R on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Transfer of immune complexes from erythrocyte CR1 to mouse macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

An activating immunoreceptor complex formed by NKG2D and DAP10

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901659-5

7 January 2021

10.1016/S0167-5699(00)01659-5

Identifiers

DOI

1 reference

30 July 2017

1 reference